Optimal management of the T1G3 bladder cancer

Urologic Clinics of North America

Volumn 32, Issue 2, 2005, Pages 133-145

  Manoharan, Murugesan ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IMMUNOLOGIC AGENT; MITOMYCIN C; PACLITAXEL; THIOTEPA; VALRUBICIN;

BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER IRRITATION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CYSTECTOMY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; GENE THERAPY; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MICROWAVE THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 18144378376     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.02.002     Document Type: Review

References (113)

1. J. Patard, S. Moudouni, and F. Saint Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years Urology 58 2001 551 556
2. G. Jakse, W. Loidl, and G. Seeber Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 137 1987 39 43
3. C.L. Amling, J.B. Thrasher, and H.A. Frazier Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31 35
4. R. Klan, V. Loy, and H. Huland Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder J Urol 146 1991 316 318
5. D. Zaak, E. Hungerhuber, and P. Schneede Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions Cancer 95 2002 1234 1238
6. H.W. Herr The value of a second transurethral resection in evaluating patients with bladder tumors J Urol 162 1999 74 76
7. S.C. Dutta, J.A. Smith Jr., and S.B. Shappell Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy J Urol 166 2001 490 493
8. M.A. Zurkirchen, T. Sulser, and A. Gaspert Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists Urol Int 72 2004 99 102
9. M.O. Grimm, C. Steinhoff, and X. Simon Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study J Urol 170 2 Pt 1 2003 433 437
10. M. May, T. Nitzke, and C. Helke Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder Scand J Urol Nephrol 38 2004 231 235
11. R.F. Sanchez-Ortiz, W.C. Huang, and R. Mick An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma J Urol 169 2003 110 115
12. R.J. Van Gils-Gielen, W.P. Witjes, and C.T. Caris Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group Urology 45 1995 581 586
13. F. May, U. Treiber, and R. Hartung Significance of random bladder biopsies in superficial bladder cancer Eur Urol 44 2003 47 50
14. A. Van der Meijden, W. Oosterlinck, and M. Brausi Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee Eur Urol 35 1999 267 271
15. I. Taguchi, K. Gohji, and I. Hara Clinical evaluation of random biopsy of urinary bladder in patients with superficial bladder cancer Int J Urol 5 1998 30 34
16. A.W. Levi, S.R. Potter, and M.P. Schoenberg Clinical significance of denuded urothelium in bladder biopsy J Urol 166 2001 457 460
17. S. Holmang, H. Hedelin, and C. Anderstrom The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study J Urol 157 1997 800 803
18. Y. Hasui, Y. Osada, and S. Kitada Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer Urology 43 1994 782 786
19. G. Smits, E. Schaafsma, and L. Kiemeney Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression Urology 52 1998 1009 1013
20. L. Cheng, A.L. Weaver, and R.M. Neumann Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal Cancer 86 1999 1035 1043
21. H.W. Herr, R.A. Badalament, and D.A. Amato Superficial bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression J Urol 141 1989 22
22. V.W. Merz, D. Marth, and R. Kraft Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guérin for carcinoma in situ of the bladder Br J Urol 75 1995 180
23. E. Solsona, I. Iborra, and R. Dumont The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685
24. F. Millan-Rodriguez, G. Chechile-Toniolo, and J. Salvador-Bayarri Multivariate analysis of the prognostic factors of primary superficial bladder cancer J Urol 163 2000 73 78
25. C. Pfister, J.M. Flaman, and F. Dunet p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guérin therapy J Urol 162 1999 69
26. T. Lebret, V. Becette, and M. Barbagelatta Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer J Urol 159 1998 788
27. L. Lacombe, G. Dalbagni, and Z.F. Zhang Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome J Clin Oncol 14 1996 2646
28. F. Pages, T.A. Flam, and A. Vieillefond p53 status does not predict initial clinical response to bacillus Calmette-Guérin intravesical therapy in T1 bladder tumors J Urol 159 1998 1079
29. J. Llopis, A. Alcaraz, and M.J. Ribal p53 expression predicts progression and poor survival in T1 bladder tumors Eur Urol 37 2000 644
30. A.S. Sarkis, G. Dalbagni, and C. Cordon-Cardo Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression J Natl Cancer Inst 85 1993 53
31. D. Esrig, D. Elmajian, and S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259
32. G. Steiner, E. Bierhoff, and D. Schmidt p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder: a helpful parameter in guiding the decision for or against cystectomy? Eur J Cancer 36 2000 610
33. A. Lopez-Beltran, R.J. Luque, and J. Alvarez-Kindelan Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1) Eur Urol 45 2004 606 612
34. D.L. Lamm, B.A. Blumenstein, and E.D. Crawford Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group Study Urol Oncol 1 1995 119
35. P.U. Malmström, H. Wijkström, and C. Lundholm 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group J Urol 161 1999 1124
36. P. Malmström Improved patient outcomes with BCG immunotherapy vs. chemotherapy: Swedish and worldwide experience Eur Urol Suppl 37 2000 16
37. W. Zhao, J.S. Schorey, and M. Bong-Mastek Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity Int J Cancer 86 2000 83
38. Y. Luo, X. Chen, and T.M. Downs INF-alpha 2b enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis BCG immunotherapy J Immunol 162 1999 2399
39. A. Bohle, A. Thanhauser, and A.J. Ulmer Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon J Urol 150 1993 1932
40. T.L. Ratliff, E.O. Haaff, and W.J. Catalona Interleukin-2 production during intravesical bacille Calmette-Guérin therapy for bladder cancer Clin Immunol Immunopathol 40 1986 375
41. M.S. Cookson, and M.F. Sarosdy Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy J Urol 148 1992 797
42. M. Brake, H. Loertzer, and R. Horsch Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin J Urol 163 2000 1697
43. H.W. Herr Tumor progression and survival in patients with T1G3 bladder tumours: 15-year outcome Br J Urol 80 1997 762
44. R. Hurle, A. Losa, A. Manzetti, and A. Lembo Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up Urology 54 2 1999 258 263
45. M.D. Shelley, J.B. Court, and H. Kynaston Intravesical bacillus Calmette-Guérin in Ta and T1 bladder cancer (Cochrane Review) Cochrane Database Syst Rev 4 2000 CD001986
46. D.L. Lamm Bacillus Calmette-Guérin immunotherapy for bladder cancer J Urol 134 1985 40
47. H.W. Herr, C.M. Pinsky, and W.F. Whitmore Jr. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors Urology 25 1985 119
48. H. Rubben, W. Lutzeyer, and N. Fischer Natural history and treatment of low and high risk superficial bladder tumors J Urol 139 1988 283
49. M.D. Melekos, H. Chionis, and A. Pantazakos Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule J Urol 149 1993 744
50. J.A. Smith Jr., R.F. Labasky, and A.T. Cockett Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). American Urological Association J Urol 162 1999 1697
51. C. Lundholm, B.J. Norlén, and P. Ekman A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma J Urol 156 1996 372
52. S.A. Brosman Bacillus Calmette-Guérin immunotherapy: techniques and results Urol Clin North Am 19 1992 557
53. L.R. Kavoussi, R.J. Torrence, and D.P. Gillen Results of 6 weekly intravesical BCG instillations on the treatment of superficial bladder tumors J Urol 139 1988 935
54. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ TCC of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124
55. A.P.M. Van der Meijden, M. Brausi, and V. Zambon Intravesical instillation of epirubicin, B. C. G., and B. C. G. plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group Randomized Phase III trial J Urol 166 2001 476
56. R.A. Badalament, and R.N. Farah Treatment of superficial bladder cancer with intravesical chemotherapy Semin Surg Oncol 13 1997 335
57. H. Sekine, I. Fukui, and T. Yamada Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result J Urol 151 1994 27
58. J.L. Duque, and K.R. Loughlin An overview of the treatment of superficial bladder cancer: intravesical chemotherapy Urol Clin North Am 27 2000 125
59. R.P. Huben Intravesical chemotherapy versus immunotherapy for superficial bladder cancer Semin Urol Oncol 14 1996 17
60. E. Solsona, I. Iborra, and J.V. Ricos Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and low-term followup J Urol 161 1999 1120
61. S. Isaka, T. Okano, and K. Abe Sequential instillation therapy with mitomycin C and Adriamycin for superficial bladder cancer Cancer Chemother Pharmacol 30 1992 s41
62. I. Fukui, K. Kihara, and H. Sekine Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response Cancer Chemother Pharmacol 30 1992 37
63. W. Oosterlinck, K.H. Kurth, and F. Schroder A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder J Urol 149 1993 749 752
64. D.A. Tolley, M.K. Parmar, and K.M. Grigor The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up J Urol 155 1996 1233 1238
65. E. Solsona, I. Iborra, and J.V. Ricos Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup J Urol 161 1999 1120 1123
66. C. Bouffioux, K.H. Kurth, and A. Bono Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group J Urol 153 3 Pt 2 1995 934 941
67. C. Pfister, P. Lande, and J.M. Herve T1G3 bladder tumors: the respective role of BCG and cystectomy Prog Urol 5 1995 231 237
68. T. Lebret, F. Gaudez, and J.M. Herve Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success Eur Urol 34 1998 67 72
69. M. Brake, H. Loertzer, and R. Horsch Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin J Urol 163 2000 1697 1701
70. J.J. Patard, S. Moudouni, and F. Saint Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years Urology 58 2001 551 556
71. J.N. Kulkarni, and R. Gupta Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin Danish 1331 strain BJU Int 90 2002 554 557
72. J. Bogdanovic, G. Marusic, and J. Djozic The management of T1G3 bladder cancer Urol Int 69 2002 263 265
73. M. Peyromaure, F. Guerin, and D. Amsellem-Ouazana Intravesical bacillus Calmette-Guérin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients J Urol 169 2003 2110 2112
74. O. Shahin, G.N. Thalmann, and C. Rentsch A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 2003 96 100
75. H.W. Herr, and G. Dalbagni Defining bacillus Calmette-Guérin refractory superficial bladder tumors J Urol 169 2003 1706 1708
76. V. Pansadoro, P. Emiliozzi, and F. De Paula Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience Urology 59 2002 227 231
77. P.U. Malmstrom, H. Wijkstrom, and C. Lundholm 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group J Urol 161 1999 1124 1127
78. G. Steinberg, R. Bahnson, and S. Brosman Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder J Urol 163 2000 761 767
79. A.S. Belldegrun, J.R. Franklin, and M.A. O'Donnell Superficial bladder cancer: the role of interferon-alpha J Urol 159 1998 1793 1801
80. S.P. Punnen, J.L. Chin, and M.A. Jewett Management of bacillus Calmette-Guérin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy Can J Urol 10 2003 1790 1795
81. J.S. Lam, M.C. Benson, and M.A. O'Donnell Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity Urol Oncol 21 2003 354 360
82. M.A. O'Donnell, K. Lilli, and C. Leopold Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2B for superficial bladder cancer J Urol 176 2004 888 892
83. J. Dunst, R. Sauer, and K.M. Schrott Organ-sparing treatment of advanced bladder cancer: a 10-year experience Int J Radiat Oncol Biol Phys 30 1994 261 266
84. C. Rodel, J. Dunst, and G.G. Grabenbauer Radiotherapy is an effective treatment for high-risk T1-bladder cancer Strahlenther Onkol 177 2001 82 88
85. A.P. Berger, H. Steiner, and A. Stenzl Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single center study Urology 61 2003 338 341
86. M.S. Cookson, H.W. Herr, and Z.F. Zhang The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62
87. B.S. Malkowicz, P. Nichols, and G. Lieskovsky The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, PI, PIS and P2) J Urol 144 1990 641
88. B. Malavaud T1G3 bladder tumours: the case for radical cystectomy Eur Urol 45 2004 406 410
89. H.W. Herr A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival [editorial comment] J Urol 169 2003 96 100
90. L. Dyrskjot, T. Thykjaer, and M. Kruhoffer Identifying distinct classes of bladder carcinoma using microarrays Nat Genet 33 2003 90 96
91. H.W. Herr, and P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296 1299
92. S. Hart, E.C. Skinner, and B.E. Meyerowitz Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral Kock pouch J Urol 162 1999 77 81
93. L. Henningsohn, K. Steven, and E.B. Kallestrup Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population J Urol 168 2002 168 174
94. R.E. Hautman, R. dePetriconi, and H.W. Gottfried The ileal neobladder: complications and functional results in 363 patients after 11 years of followup J Urol 161 1999 422
95. M.S. Soloway, M. Sofer, and A. Vaidya Contemporary management of stage T1 transitional cell carcinoma of the bladder J Urol 167 2002 1573 1583
96. E. Rintala, K. Jauhiainen, and E. Kaasinene Alternating mitomycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group J Urol 156 1996 56
97. J.A. Witjes, C.T. Caris, and N.A. Mungan Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guérin versus mitomycin C alone in patients with superficial bladder cancer J Urol 160 1998 1668
98. B. Ali-El-Dein, A. Nabeeh, and E.H. Ismail Sequential bacillus Calmette-Guérin and epirubicin versus bacillus Calmette-Guérin alone for superficial bladder tumors: a randomized prospective study J Urol 162 1999 339
99. C.Y. Bilen, H. Ozen, and F.T. Aki Clinical experience with BCG alone versus BCG plus epirubicin Int J Urol 7 2000 206
100. A.V. Bono, J.A. Lovisolo, and G. Saredi Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer Eur Urol 37 2000 478
101. V. Serretta, C. Pavone, and G.B. Ingargiola TUR and adjuvant inravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years Eur Urol 45 2004 730 735
102. G. Dalbagni, P. Russo, and J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder [see comment] J Clin Oncol 20 2002 3193 3198
103. G. Dalbagni, M. Mazumdar, and P. Russo Phase II trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder J Urol 171 4 2004 (Suppl):72 (abstract)
104. M. Laufer, S. Ramalingam, and M.P. Schoenberg Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study J Clin Oncol 21 2003 697 703
105. E. De Berardinis, G. Antonini, and G.J. Peters Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation BJU Int 93 2004 491 494
106. J.L. Au, J. Kalns, and Y. Gan Pharmacologic effects of paclitaxel in human bladder tumors Cancer Chemother Pharmacol 41 1997 69 74
107. D. Chen, D. Song, and M.G. Wientjes Effect of dimethyl sulfoxide on bladder tissue penetration of inravesical paclitaxel Clin Cancer Res 9 2003 363 369
108. L.G. Gomella, M.J. Mastrangelo, and P.A. McCue Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer J Urol 166 2001 1291 1295
109. A. Morales, I. Voccia, and G. Steinhoff Mycobacterium phlei cell wall extract for the treatment of superficial bladder cancer: final results of a phase 2 trial J Urol 171 2004 74
110. R.J. Doll, P. Kirschmeier, and W.R. Bishop Farnesyltransferase inhibitors as anticancer agents Curr Opin Drug Discov Dev 7 2004 478 486
111. N. Thiounn, F. Pages, and A. Mejean Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells J Urol 168 2002 2373 2376
112. R. Colombo, L.F. Da Pozzo, and A. Salonia Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma J Clin Oncol 21 2003 4270 4276
113. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777 782